| SELL | 0.285 | Peter Hodson | At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling. | 2005-11-17 | |
| BUY | 0.670 | Robert Floyd | A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go. | 2005-09-29 | |
| BUY | 0.840 | Robert Floyd | One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation. | 2004-06-28 | |
| DON'T BUY | 0.860 | Robert Floyd | Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price. | 2004-06-01 | |
| WEAK BUY | 1.060 | Hugh McCauley | Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little. | 2004-04-19 | |
| DON'T BUY | 1.040 | Lou Schizas | Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses. | 2003-12-09 | |
| BUY | 1.070 | Robert Floyd | A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products. | 2003-12-08 | |
| BUY | 1.290 | Robert Floyd | Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile. | 2003-09-22 | |
| DON'T BUY | 1.230 | Mark Jackson, CFA | High-risk company.You should own five or six in this sector in order to spread the risks. | 2003-08-20 | |
| BUY on WEAKNESS | 1.180 | Larry Berman CFA, CMT, CTA | Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low. | 2003-07-21 | |
| BUY | 1.250 | Robert Floyd | Just did a financing to extend development on new products. Sees further improvement. | 2003-07-04 | |
| DON'T BUY | 1.230 | Jonathen Wellum, B. Comm, B. Sc | Has never generated any degree of profitability. Speculative. | 2003-06-24 | |
| BUY | 1.410 | John Sinkins, CFA | Received patent approval on one of their processes. New drugs for cancer are being tested in Mexico and USA. You have to keep an eye on this one. | 2003-05-14 | |
| BUY | 1.300 | Peter Hodson | Well managed. Decent balance sheet. Has a huge beta which means that as the market goes up, this goes up a lot more. Very liquid. | 2003-05-12 | |
| WEAK BUY | 1.390 | Michael Smedley | Looks positive. Has a big following. | 2003-05-02 | |
| PAST TOP PICK | 1.600 | Robert Floyd | (Was a top pick on Mar 27. Up 6%.) Still likes. Expects a lot more upside. | 2003-04-25 | |
| BUY | 0.980 | Robert Floyd | Should have a lot of upside, but earnings will take a while. Has one application in stage 3 with FDA. Good price. | 2003-04-10 | |
| WEAK BUY | 0.980 | John Sinkins, CFA | A worthwhile speculative play. | 2003-03-31 | |
| TOP PICK | 0.850 | Robert Floyd | Good products nearing approval. Can move up dramatically. | 2003-03-27 | |
| DON'T BUY | 0.560 | Larry Berman CFA, CMT, CTA | Volatile. In a downtrend. Probably getting near a low. | 2002-09-03 | |
| DON'T BUY | 1.080 | Robert Floyd | News driven. Could be a long wait. | 2002-02-01 | |
| BUY | 1.250 | Ray Steele | Good products in their pipeline. Good management. | 2002-01-16 | |
| BUY | 1.170 | Robert Floyd | Could have some upside. Good management/cash position. | 2001-12-21 | |
| TOP PICK | 1.170 | Ray Steele | Making progress in the FDA phases. Biotechs will be good. A cheap price. | 2001-12-21 | |
| DON'T BUY | 1.160 | Robert Floyd | New joint ventures but growth may take awhile. | 2001-11-09 | |
| DON'T BUY | 1.250 | Martin Hubbes, CFA | Products are too early in their stage. Too expensive. Have a lot of cash. | 2001-08-24 | |
| DON'T BUY | 1.600 | David Driscoll | A hit and miss sector. Volatile. | 2001-06-04 | |
| DON'T BUY | 1.720 | Ross Healey | Speculative. No earnings. Low price, but could drop evenmore. | 2001-05-15 | |
| BUY | 1.800 | Malvin Spooner | Expects good results by year end on their product. A fan. | 2001-05-10 | |
| DON'T BUY | 1.650 | Glenn Paradis, BA, CFA | Smaller company and only one product. | 2001-05-04 | |
| DON'T BUY | 1.620 | Ray Steele | Good strategy. In the early stages, so is risky. Very small company. | 2001-05-01 | |
| BUY | 1.720 | Robert Floyd | Interesting company. Well capitalized. A lot of cancer solutions. | 2001-03-15 | |
| WEAK BUY | 1.700 | Malvin Spooner | Usually BURNS money rather than earning any. | 2001-03-14 | |
| WAIT | 2.130 | Phil Smith | High risk/high return. Early days yet. Only one drug. | 2001-02-21 | |
| BUY | 2.590 | Robert Floyd | Likes. Good balance sheet and cash position. News is good and like their sector. | 2001-02-19 | |
| DON'T BUY | 2.000 | Ray Steele | Getting hit because of nervous market. Risky | 2001-02-14 | |
| BUY | 2.440 | Glenn Paradis, BA, CFA | Attractive at current valuations. Has some promise | 2001-02-01 | |
| BUY on WEAKNESS | 1.840 | Steven Misener | A trading stock as compared to a holding stock. Volatile | 2001-01-23 | |
| STRONG BUY | 1.860 | Pier Donnini | Likes good prospects. Undervalued. RISK/Reward over next few months = REWARD | 2001-01-19 | |
| DON'T BUY | 1.820 | John Sinkins, CFA | Speculative. Have to know/understand them well | 2001-01-12 | |
| WAIT | 1.830 | Fred Ketchen | Good company, but still developing their drug | 2000-12-29 | |
| BUY | 2.000 | Glenn Paradis, BA, CFA | OK, but diversify. Good platform. To move, it needs news to drive | 2000-10-13 | |
Experts that have talked about Lorus Therapeutics
Rss Top Picks Feed
